Clinical Pharmacy Notes by Dr. Mohammed Ali Alobaidy

Clinical Pharmacy Notes by Dr. Mohammed Ali Alobaidy

Chapter 1: Anemia

Definition of Anemia

Anemia is defined as a reduction in normal hemoglobin levels in the blood. The World Health Organization (WHO) defines anemia in adults as hemoglobin levels of less than 130 g/L for males and less than 120 g/L for females.

Epidemiology

Anemia has a high prevalence worldwide. The lowest prevalence occurs in men, while pregnant women have a lower threshold for anemia, making it more common in that population. Hemoglobin levels can vary slightly by altitude and can be higher in smokers. Males typically have higher hemoglobin levels due to the influence of androgens, which stimulate hemoglobin production. In elderly patients, the distinction between hemoglobin values in men and women is less pronounced. Hemoglobin is also influenced by fluid status; for example, dehydration can cause artificially elevated hemoglobin levels due to reduced plasma volume, while increased plasma volume from conditions such as pregnancy can result in diluted hemoglobin levels. Importantly, the hemoglobin level does not always correlate with the degree of symptoms experienced.

Etiology of Anemia

The low hemoglobin levels associated with anemia can arise from:

  • Increased Hemoglobin Loss
    • Hemorrhage: Loss of red blood cells due to bleeding.
    • Hemolysis: Destruction of red blood cells.
  • Reduced Hemoglobin Synthesis
    • Nutritional Deficiencies: Lack of essential nutrients.
    • Bone Marrow Failure: Conditions affecting the production of blood cells in the bone marrow.
Hemopoiesis

Hemopoiesis refers to the formation of blood cells, including white blood cells, red blood cells, and platelets, primarily occurring in the bone marrow and, to a lesser extent, in the liver and spleen during times of increased demand. All blood cells originate from pluripotent hemopoietic stem cells with the potential to differentiate into any blood cell type.

Processes of Erythropoiesis
  • Stem Cell Proliferation and Differentiation: Stem cells proliferate and differentiate into progenitor cells.
  • Synthesis of Hemoglobin, DNA, and RNA: Hemoglobin is composed of four globin chains (α1, α2, β1, β2), each with one haem molecule. Haem is formed in mitochondria through the combination of protoporphyrin and iron (Fe2+) with pyridoxine as a co-factor. Each haem molecule can carry one oxygen molecule.
  • Formation of Normoblasts: Normoblasts represent the final stage of production within the bone marrow. Approximately 10-15% of normoblasts die without producing red blood cells, while the majority release reticulocytes into circulation.
  • Reticulocyte Maturation: Reticulocytes (1-3% of red blood cells) mature into red blood cells in about 48 hours. Increased reticulocyte percentages can occur after acute blood loss.
    • Regulation by Growth Factors: Erythropoiesis is regulated primarily by erythropoietin, produced mainly in the renal cortex, which increases in response to reduced oxygen tension or hypoxia.
Factors Required for Erythropoiesis

Essential factors include:

  • Iron, cobalt, several vitamins (B1, B6, B12, C, E), riboflavin, and hormones such as androgens and thyroxine.
  • Hepcidin, an inflammatory protein that suppresses iron absorption, decreases during erythropoiesis.
Erythropoiesis in Chronic Conditions
  • Conditions like rheumatoid arthritis, cancer, sickle cell disease, impaired lung function, and cardiovascular dysfunction can suppress erythropoietin production. Renal failure leads to insufficient erythropoietin production, contributing to anemia.
Lifecycle of Red Blood Cells
  • Normal Lifespan: About 120 days for erythrocytes. Millions of erythrocytes enter circulation daily, and they are destroyed in the spleen and bone marrow at the end of their lifespan. Iron from hemoglobin is reused, while parts of the globin chains are excreted as bilirubin by the liver.
Clinical Manifestations of Anemia
  1. General Symptoms:
    • Tiredness
    • Lethargy
    • Exercise intolerance
  2. Cerebral Symptoms:
    • Reduced cognition
    • Confusion
    • Headaches
    • Light-headedness
  3. Severe/Longstanding Anemia Symptoms:
    • Shortness of breath
    • Angina
    • Tachycardia
    • Palpitations
    • Heart failure
  4. Rapid Onset Anemia (e.g., due to Hemorrhage):
    • Shock
    • Collapse
    • Dyspnea
    • Tachycardia
Investigations for Anemia
  1. Medical History and Patient Evaluation:
    • Note medications and recent travel experiences.
    • Assess for underlying conditions like liver disease or chronic renal failure.
  2. Initial Blood Tests:
    • Full blood count (FBC)
    • Hemoglobin (Hb) levels
    • Mean corpuscular volume (MCV)
    • Mean cell hemoglobin (MCH)
  3. MCV and MCH Analysis:
    • MCV indicates microcytic, normocytic, or macrocytic anemia.
    • MCH reflects hemoglobin density.
  4. Additional Indicators:
    • Low leukocyte and platelet counts may suggest bone marrow suppression (pancytopenia).
  5. Blood Film Examination:
    • Stained blood film examines red blood cell morphology.
  6. Hematinic Tests:
    • Vitamin B12, folate, ferritin, iron, and transferrin levels (iron profiling).
  7. Additional Tests:
    • Liver function tests, renal function tests, thyroid function tests.
  8. Further Diagnostics:
    • Bone marrow aspiration or biopsy if the peripheral blood tests do not identify the cause.
Iron-Deficiency Anemia (IDA)
  • Etiology:
    • The most common cause is blood loss, especially menstrual loss in women and gastrointestinal bleeding in men.
    • Other causes include hemorrhoids, nosebleeds, postpartum hemorrhage.
  • Pathophysiology:
    • Iron Absorption: Primarily from the duodenum and jejunum. Haem iron (from meat) is better absorbed than non-haem iron (from plants). Phosphates and phytates can form complexes with iron that inhibit absorption, whereas ascorbic acid enhances absorption. The average dietary intake of iron is about 15 mg, with 10% absorbed.
    • Iron Transport: Iron is carried by transferrin in the blood.
    • The body typically contains about 50 mg/kg of iron: 65% in hemoglobin, 10% in myoglobulin, and the rest in the liver, macrophages, and bone marrow.
    • Iron Loss: Daily losses average 0.5-1 mg, increasing in women by another 0.5-1 mg due to menstruation, and it also increases during pregnancy where requirements rise by 1-2 mg/day. Hepcidin level regulates iron uptake from the duodenum.
  • Clinical Manifestations of IDA:
    1. General symptoms include fatigue, weakness, pallor, and breathlessness, with a risk of heart failure in severe cases.
    2. Chronic IDA symptoms may include koilonychia, dysphagia, and pica (cravings for non-nutritive substances).
  • Investigations:
    • Initial blood tests (FBC shows low MCV, MCH; stained blood film shows microcytic, hypochromic red blood cells, poikilocytes)
    • Ferritin level reveals low iron stores (often <15 micrograms/L); transferrin saturation may be low, and total iron-binding capacity is often high.
    • Additional tests should exclude other types of anemia and evaluate responses to iron replacement.
  • Treatment of IDA:
    • Iron Replacement Therapy: To restore hemoglobin levels, replenish iron stores, and prevent recurrence. Generally, ferrous sulfate is prescribed (200 mg tablets, twice or thrice daily). Slow-release preparations are not recommended.
    • Management: Monitor hemoglobin levels within 2-4 weeks, aiming for a rise of 20 g/L in that time. If no response is noted, reassess the diagnosis. Continue iron until iron stores are adequate (sufficient ferritin levels).
  • Patient Care: Education on gastrointestinal side effects and black stools, managing medication interactions, recommending dietary sources of iron, and considering parenteral iron if oral iron is poorly tolerated.
Anemia of Chronic Disease
Epidemiology

This condition represents the second most common form of anemia after IDA and is often associated with various inflammatory diseases such as arthritis, cancers, inflammatory bowel conditions, HIV, and others. It is also referred to as "anemia of inflammation" or "anemia of chronic inflammation."

Etiology
  • In chronic disease, renal production of erythropoietin is inhibited by inflammatory cytokines. Increased hepcidin levels reduce iron absorption and lower the release of iron from body stores, impairing erythropoiesis.
  • Although iron stores are sufficient, patients present with anemia due to the failure to utilize available iron.
  • In morbid conditions like cancers, cytotoxic treatments can worsen erythrocyte production through their effects on bone marrow.
  • Chronic renal dysfunction and heart failure also reduce erythropoietin levels, leading to anemia.
Pathophysiology

Infections, chronic inflammation, and cancer lead to increased hepcidin production, which sequesters iron and inhibits erythropoiesis, resulting in normocytic anemia that can prevent proper cellular respiration and increase white blood cell production that competes for bone marrow resources, thus leading to fewer red blood cells.

Clinical Manifestations

General symptoms of anemia may be compounded by the primary chronic inflammatory condition, which leads to a reduced quality of life.

Investigations

Typically detected on a full blood count, which may show normocytic or microcytic anemia, but lesser in severity than IDA. Ferritin remains normal or elevated against inflammation.

Treatment

Addressing the underlying chronic condition is crucial; however, blood transfusions are infrequently required. Iron therapy isn't indicated as this group presents with functional iron deficiency, and elevated hepcidin levels inhibit oral iron absorption.

Sideroblastic Anemias

Sideroblastic anemia is characterized by the presence of ring sideroblasts in the bone marrow aspirates and impaired synthesis of hemoglobin despite having adequate iron stores. Both hereditary and acquired forms are recognized. Hereditary forms are rare and linked to reduced activity of the enzyme 5-aminolevulinate synthase (ALAS), involved in heme synthesis.

  • Acquired forms arise from conditions linked to myelodysplastic syndromes, copper deficiency, drug toxicity, etc. Drugs and toxins such as alcohol, isoniazid, and certain antibiotics can induce sideroblastic anemia.
Treatment
  • Acquired Forms:
    • Address any reversible factors and consider nutritional supplementation.
  • Hereditary Forms:
    • Administer blood transfusions as necessary.
    • Pyridoxine (vitamin B6) therapy can also be beneficial.
Megaloblastic Anemias

Megaloblastic anemias occur due to deficiencies in vitamin B12 or folate and are characterized by macrocytic red blood cells. The main causes are dietary insufficiencies or absorption issues linked to gastrointestinal diseases like coeliac disease.

Investigations for Megaloblastic Anemia

A complete blood count supporting macrocytosis, serum vitamin levels of B12 and folate, along with parental history and dietary evaluation, will help in determining deficiencies.

Treatment
  • Vitamin B12: Administered intramuscularly for active deficiency.
  • Folate: Supplement 5 mg daily; typically replete within 4 months.
Note on Treatment Risks

Ensure when vitamin B12 is deficient to address this prior to folate therapy, to prevent exacerbating neuropathy or causing spinal degeneration.

Investigation Techniques for Anemia

  1. Full Blood Count: basic screening tests for anemia.
  2. Targeted Hematinics: tests for relevant deficiencies (i.e., vitamin B12).
  3. Reticulocyte Count: measuring erythropoietic activity.
  4. Blood Smears: Morphological evaluation.
  5. Bone Marrow Study: for cases of suspected bone marrow production disorders.

Patient Management

  1. Dietary Adjustments appropriate for the anemia type, ensuring balanced nutrition and addressing side effects from therapies (such as iron absorption variables).
  2. Long-Term Monitoring: Regular follow-ups post anemia treatment, including CBC, iron profiles, and overall dietary habits, to ascertain the success of management strategies and to observe any remission in anemia.
  3. Comorbidity Evaluations, especially in chronic settings, to rule out other underlying or complicating factors.

Chapter 4: Diabetes Management

Overview of Diabetes

Diabetes mellitus is a chronic condition characterized by hyperglycemia due to insufficient insulin production and/or insulin resistance.

Types of Diabetes
  1. Type 1 Diabetes: Result of autoimmunity against pancreatic β-cells, leading to insulin deficiency.
  2. Type 2 Diabetes: Associated with lifestyle factors and resulting in both insulin resistance and inadequate insulin secretion.
  3. Gestational Diabetes: Defined by glucose intolerance during pregnancy.
  4. Other Specified Types: Including MODY and secondary due to other conditions or medications.
Pathophysiology
  • Insufficient production leads to high levels of circulating glucose, causing metabolic and vascular complications.
Common Symptoms of Diabetes
  • Polyuria, polydipsia, weight loss (especially in type 1), fatigue, blurred vision, increased infections.
Diagnosis
  • Use of HbA1c > 6.5%, random glucose tests, or fasting glucose levels > 126 mg/dL to confirm diabetes.
Management Goals
  • Strict blood glucose control to prevent complications, often through lifestyle changes (diet and exercise), pharmacological intervention (metformin as a gold standard for Type 2).
Pharmacotherapy

When lifestyle changes are inadequate, the following therapeutic options are available:

  • Biguanides (e.g., Metformin): Inhibits hepatic glucose production and increases peripheral sensitivity.
  • Sulfonylureas: Stimulate insulin secretion from the pancreas.
  • DPP4 Inhibitors and GLP-1 Agonists: Enhance incretin effect to increase insulin secretion and decrease glucagon levels.
  • SGLT2 Inhibitors: Increase renal glucose excretion, facilitating weight loss.
Monitoring

Regular monitoring of HbA1c, finger-stick glucose levels, and assessment of complications. Patients on high-risk medications (antidiabetics) should be monitored for hypoglycemia, especially in the context of organ failure.

Patient Education

Include dietary and lifestyle counseling, focusing on tailored individual plans to engage patients to promote adherence to management strategies. Regular follow-ups to reinforce education and assess perspective health goals.

Long-Term Management
  • Comprehensive screening for complications should be part of the care plan, including foot exams, eye exams, and microalbuminuria screening annually.

This guide encompasses essential aspects of clinical pharmacy aligned with the notes provided by Dr. Mohammed Ali Alobaidy on anemia and diabetes management. Each section is revised to provide clarity and detail.